Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer

NCT02676986 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT02676986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02676986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Completed
Start date
August 10, 2015
Completion date
December 31, 2016
Enrollment
221 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

primary breast cancer ar+ve tnbn, primary breast cancer er+ve